1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Helsinn's anamorelin approval chances plummet on mixed PhIII cachexia data

 
• By Gemma Collier

Switzerland's Helsinn Group has presented results from two Phase III studies of cachexia drug anamorelin, with which it is planning 2015 filings in the US and Europe. But while the drug hit one of its co-primary endpoints, its failure to hit the second makes its success questionable.

Switzerland's Helsinn Group has presented results from two Phase III studies of cachexia drug anamorelin, with which it is planning 2015 filings in the US and Europe. But while the drug hit one of its co-primary endpoints, its failure to hit the second makes its success questionable.

The 12-week studies, ROMANA 1 and ROMANA 2, evaluated the effect of anamorelin on anorexia-cachexia in patients with non-small cell...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

More from Therapy Areas